Indivior PLC

LSE:INDV Stock Report

Market Cap: UK£1.1b

Indivior Valuation

Is INDV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INDV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: INDV (£8.53) is trading below our estimate of fair value (£184.04)

Significantly Below Fair Value: INDV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INDV?

Key metric: As INDV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INDV. This is calculated by dividing INDV's market cap by their current revenue.
What is INDV's PS Ratio?
PS Ratio1.1x
SalesUS$1.18b
Market CapUS$1.36b

Price to Sales Ratio vs Peers

How does INDV's PS Ratio compare to its peers?

The above table shows the PS ratio for INDV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
HCM HUTCHMED (China)
4.9x18.0%UK£2.4b
DPH Dechra Pharmaceuticals
5.8x7.9%UK£4.4b
APH Alliance Pharma
1.3x5.2%UK£246.0m
HIK Hikma Pharmaceuticals
1.8x3.8%UK£4.3b
INDV Indivior
1.1x5.5%UK£1.1b

Price-To-Sales vs Peers: INDV is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (3.4x).

Price to Sales Ratio vs Industry

How does INDV's PS Ratio compare vs other companies in the GB Pharmaceuticals Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x5.9%US$55.97m
No more companies available in this PS range
INDV 1.1xIndustry Avg. 2.9xNo. of Companies6PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: INDV is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is INDV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INDV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: INDV is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INDV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£8.53
UK£13.87
+62.7%
16.5%UK£18.17UK£11.57n/a5
Nov ’25UK£7.10
UK£13.87
+95.5%
16.5%UK£18.17UK£11.57n/a5
Oct ’25UK£7.27
UK£17.81
+145.0%
11.7%UK£20.96UK£14.65n/a5
Sep ’25UK£9.37
UK£18.92
+102.0%
18.0%UK£25.16UK£15.03n/a5
Aug ’25UK£10.57
UK£19.95
+88.7%
19.3%UK£24.97UK£14.92n/a5
Jul ’25UK£12.30
UK£24.40
+98.4%
2.6%UK£25.21UK£23.51n/a4
Jun ’25UK£14.45
UK£24.25
+67.8%
2.3%UK£25.01UK£23.51n/a4
May ’25UK£14.28
UK£24.78
+73.5%
1.1%UK£24.96UK£24.41n/a3
Apr ’25UK£16.94
UK£24.80
+46.4%
1.8%UK£25.23UK£24.17n/a3
Mar ’25UK£17.64
UK£23.83
+35.1%
6.8%UK£25.01UK£21.55n/a3
Feb ’25UK£13.51
UK£24.12
+78.6%
7.9%UK£25.94UK£21.49n/a3
Jan ’25UK£11.85
UK£24.27
+104.8%
7.9%UK£26.10UK£21.62n/a3
Dec ’24UK£13.00
UK£22.84
+75.7%
11.2%UK£26.14UK£19.39n/a4
Nov ’24UK£15.93
UK£24.55
+54.1%
11.0%UK£27.31UK£20.10UK£7.104
Oct ’24UK£17.79
UK£24.17
+35.8%
11.0%UK£26.97UK£19.30UK£7.275
Sep ’24UK£18.19
UK£24.17
+32.9%
11.0%UK£26.97UK£19.30UK£9.375
Aug ’24UK£17.88
UK£24.84
+39.0%
3.0%UK£25.71UK£23.64UK£10.574
Jul ’24UK£18.23
UK£23.82
+30.7%
3.9%UK£25.02UK£22.87UK£12.304
Jun ’24UK£14.50
UK£24.41
+68.3%
3.8%UK£25.51UK£23.31UK£14.454
May ’24UK£15.26
UK£23.60
+54.7%
6.9%UK£25.01UK£21.02UK£14.284
Apr ’24UK£13.85
UK£23.62
+70.5%
6.6%UK£24.95UK£21.14UK£16.944
Mar ’24UK£15.12
UK£23.62
+56.2%
6.6%UK£24.95UK£21.14UK£17.644
Feb ’24UK£18.92
UK£24.91
+31.7%
4.3%UK£25.78UK£23.14UK£13.514
Jan ’24UK£18.52
UK£22.02
+18.9%
5.5%UK£23.97UK£20.83UK£11.854
Dec ’23UK£17.03
UK£21.48
+26.1%
3.3%UK£22.30UK£20.56UK£13.004
Nov ’23UK£16.80
UK£22.04
+31.2%
2.9%UK£23.01UK£21.22UK£15.934

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%